Status:
RECRUITING
Treatment of Tinnitus With Migraine Medications
Lead Sponsor:
University of California, Irvine
Conditions:
Tinnitus, Subjective
Tinnitus
Eligibility:
All Genders
25-85 years
Phase:
PHASE4
Brief Summary
Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. It is well-understood t...
Detailed Description
This study is 8 weeks in duration. There are three arms in the experiment: the first is nortriptyline (7.5 mg) plus topiramate (10 mg), the second is verapamil (30 mg) plus paroxetine (4 mg), and the ...
Eligibility Criteria
Inclusion
- Patients with moderate to severe tinnitus.
- Male or female between the ages of 25 to 85 years.
- Subject must be compliant with the medication and attend study visits.
- Must be able to read and write in the English language to provide consenting.
Exclusion
- Pregnancy will result in automatic exclusion from the study. Rule out of pregnancy will be done by a urine pregnancy test to confirm the situation for all women who are of child bearing potential.
- Subject with history of an adverse reaction to medication being prescribed.
- Subject suffers from a medical condition or has history that may be concerning to the investigators clinical opinion.
- All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.
Key Trial Info
Start Date :
September 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04404439
Start Date
September 26 2019
End Date
December 30 2023
Last Update
January 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine Medical Center ENT Clinic (Pavilion 2)
Orange, California, United States, 92868